PMC:7102591 / 13585-14708 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"449","span":{"begin":991,"end":994},"obj":"Gene"},{"id":"450","span":{"begin":68,"end":76},"obj":"Species"},{"id":"451","span":{"begin":639,"end":647},"obj":"Species"},{"id":"452","span":{"begin":972,"end":980},"obj":"Species"},{"id":"453","span":{"begin":737,"end":749},"obj":"Chemical"},{"id":"454","span":{"begin":791,"end":809},"obj":"Chemical"},{"id":"455","span":{"begin":160,"end":162},"obj":"Disease"},{"id":"456","span":{"begin":248,"end":250},"obj":"Disease"},{"id":"457","span":{"begin":390,"end":399},"obj":"Disease"},{"id":"458","span":{"begin":527,"end":536},"obj":"Disease"},{"id":"459","span":{"begin":723,"end":732},"obj":"Disease"},{"id":"460","span":{"begin":959,"end":968},"obj":"Disease"},{"id":"461","span":{"begin":1101,"end":1110},"obj":"Disease"}],"attributes":[{"id":"A449","pred":"tao:has_database_id","subj":"449","obj":"Gene:4580"},{"id":"A450","pred":"tao:has_database_id","subj":"450","obj":"Tax:9606"},{"id":"A451","pred":"tao:has_database_id","subj":"451","obj":"Tax:9606"},{"id":"A452","pred":"tao:has_database_id","subj":"452","obj":"Tax:9606"},{"id":"A453","pred":"tao:has_database_id","subj":"453","obj":"MESH:D008727"},{"id":"A454","pred":"tao:has_database_id","subj":"454","obj":"MESH:D006886"},{"id":"A455","pred":"tao:has_database_id","subj":"455","obj":"MESH:D001172"},{"id":"A456","pred":"tao:has_database_id","subj":"456","obj":"MESH:D001172"},{"id":"A457","pred":"tao:has_database_id","subj":"457","obj":"MESH:D007239"},{"id":"A458","pred":"tao:has_database_id","subj":"458","obj":"MESH:D007239"},{"id":"A459","pred":"tao:has_database_id","subj":"459","obj":"MESH:D007239"},{"id":"A460","pred":"tao:has_database_id","subj":"460","obj":"MESH:D007239"},{"id":"A461","pred":"tao:has_database_id","subj":"461","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"4.2 csDMARDs\nThe most comprehensive analysis of infectious risk in patients treated with csDMARDs is a retrospective, longitudinal study of a population-based RA cohort using an administrative database including a total of 27,710 individuals with RA and providing 162,710 person-years of follow-up [51]. Use of csDMARDs without corticosteroids was associated with a small decrease in mild infection risk (adjusted rate ratio [RR] 0.90, 95% confidence interval [95% CI] 0.88–0.93) and was not associated with increased serious infection risk (adjusted RR 0.92, 95% CI 0.85–1.0). Similarly, another retrospective analysis conducted on 1993 patients from a claim database demonstrated a slightly reduced risk of hospitalized infection for methotrexate (adjusted RR 0.81, 95% CI 0.70–0.93) and hydroxychloroquine (adjusted RR 0.74, 95% CI 0.62–0.89) [52]. A recent systematic review and meta-analysis of the literature confirmed the lack of an increased risk of infection in patients receiving MTX (RR: 1.14; 95% CI, 0.98–1.34) [53]. However, all these reports provided no data on the risk of stratified infection by pathogen."}

{"project":"LitCovid_AGAC","denotations":[{"id":"p51595s16","span":{"begin":694,"end":701},"obj":"NegReg"}],"text":"4.2 csDMARDs\nThe most comprehensive analysis of infectious risk in patients treated with csDMARDs is a retrospective, longitudinal study of a population-based RA cohort using an administrative database including a total of 27,710 individuals with RA and providing 162,710 person-years of follow-up [51]. Use of csDMARDs without corticosteroids was associated with a small decrease in mild infection risk (adjusted rate ratio [RR] 0.90, 95% confidence interval [95% CI] 0.88–0.93) and was not associated with increased serious infection risk (adjusted RR 0.92, 95% CI 0.85–1.0). Similarly, another retrospective analysis conducted on 1993 patients from a claim database demonstrated a slightly reduced risk of hospitalized infection for methotrexate (adjusted RR 0.81, 95% CI 0.70–0.93) and hydroxychloroquine (adjusted RR 0.74, 95% CI 0.62–0.89) [52]. A recent systematic review and meta-analysis of the literature confirmed the lack of an increased risk of infection in patients receiving MTX (RR: 1.14; 95% CI, 0.98–1.34) [53]. However, all these reports provided no data on the risk of stratified infection by pathogen."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T178","span":{"begin":49,"end":59},"obj":"Disease"},{"id":"T179","span":{"begin":160,"end":162},"obj":"Disease"},{"id":"T181","span":{"begin":248,"end":250},"obj":"Disease"},{"id":"T183","span":{"begin":390,"end":399},"obj":"Disease"},{"id":"T184","span":{"begin":527,"end":536},"obj":"Disease"},{"id":"T185","span":{"begin":710,"end":732},"obj":"Disease"},{"id":"T186","span":{"begin":723,"end":732},"obj":"Disease"},{"id":"T187","span":{"begin":959,"end":968},"obj":"Disease"},{"id":"T188","span":{"begin":1101,"end":1110},"obj":"Disease"}],"attributes":[{"id":"A178","pred":"mondo_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A179","pred":"mondo_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/MONDO_0005272"},{"id":"A180","pred":"mondo_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A181","pred":"mondo_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/MONDO_0005272"},{"id":"A182","pred":"mondo_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A183","pred":"mondo_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A184","pred":"mondo_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A185","pred":"mondo_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/MONDO_0043544"},{"id":"A186","pred":"mondo_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A187","pred":"mondo_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A188","pred":"mondo_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"4.2 csDMARDs\nThe most comprehensive analysis of infectious risk in patients treated with csDMARDs is a retrospective, longitudinal study of a population-based RA cohort using an administrative database including a total of 27,710 individuals with RA and providing 162,710 person-years of follow-up [51]. Use of csDMARDs without corticosteroids was associated with a small decrease in mild infection risk (adjusted rate ratio [RR] 0.90, 95% confidence interval [95% CI] 0.88–0.93) and was not associated with increased serious infection risk (adjusted RR 0.92, 95% CI 0.85–1.0). Similarly, another retrospective analysis conducted on 1993 patients from a claim database demonstrated a slightly reduced risk of hospitalized infection for methotrexate (adjusted RR 0.81, 95% CI 0.70–0.93) and hydroxychloroquine (adjusted RR 0.74, 95% CI 0.62–0.89) [52]. A recent systematic review and meta-analysis of the literature confirmed the lack of an increased risk of infection in patients receiving MTX (RR: 1.14; 95% CI, 0.98–1.34) [53]. However, all these reports provided no data on the risk of stratified infection by pathogen."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T103","span":{"begin":102,"end":103},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T104","span":{"begin":141,"end":142},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T105","span":{"begin":213,"end":214},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T106","span":{"begin":365,"end":366},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T107","span":{"begin":653,"end":654},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T108","span":{"begin":683,"end":684},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T109","span":{"begin":848,"end":850},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T110","span":{"begin":853,"end":854},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"4.2 csDMARDs\nThe most comprehensive analysis of infectious risk in patients treated with csDMARDs is a retrospective, longitudinal study of a population-based RA cohort using an administrative database including a total of 27,710 individuals with RA and providing 162,710 person-years of follow-up [51]. Use of csDMARDs without corticosteroids was associated with a small decrease in mild infection risk (adjusted rate ratio [RR] 0.90, 95% confidence interval [95% CI] 0.88–0.93) and was not associated with increased serious infection risk (adjusted RR 0.92, 95% CI 0.85–1.0). Similarly, another retrospective analysis conducted on 1993 patients from a claim database demonstrated a slightly reduced risk of hospitalized infection for methotrexate (adjusted RR 0.81, 95% CI 0.70–0.93) and hydroxychloroquine (adjusted RR 0.74, 95% CI 0.62–0.89) [52]. A recent systematic review and meta-analysis of the literature confirmed the lack of an increased risk of infection in patients receiving MTX (RR: 1.14; 95% CI, 0.98–1.34) [53]. However, all these reports provided no data on the risk of stratified infection by pathogen."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T108","span":{"begin":160,"end":162},"obj":"Chemical"},{"id":"T109","span":{"begin":248,"end":250},"obj":"Chemical"},{"id":"T110","span":{"begin":329,"end":344},"obj":"Chemical"},{"id":"T111","span":{"begin":427,"end":429},"obj":"Chemical"},{"id":"T112","span":{"begin":552,"end":554},"obj":"Chemical"},{"id":"T113","span":{"begin":737,"end":749},"obj":"Chemical"},{"id":"T115","span":{"begin":760,"end":762},"obj":"Chemical"},{"id":"T116","span":{"begin":791,"end":809},"obj":"Chemical"},{"id":"T117","span":{"begin":820,"end":822},"obj":"Chemical"},{"id":"T118","span":{"begin":991,"end":994},"obj":"Chemical"},{"id":"T119","span":{"begin":996,"end":998},"obj":"Chemical"}],"attributes":[{"id":"A108","pred":"chebi_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/CHEBI_73810"},{"id":"A109","pred":"chebi_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/CHEBI_73810"},{"id":"A110","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A111","pred":"chebi_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A112","pred":"chebi_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A113","pred":"chebi_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/CHEBI_44185"},{"id":"A114","pred":"chebi_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/CHEBI_50681"},{"id":"A115","pred":"chebi_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A116","pred":"chebi_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A117","pred":"chebi_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"},{"id":"A118","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_44185"},{"id":"A119","pred":"chebi_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"}],"text":"4.2 csDMARDs\nThe most comprehensive analysis of infectious risk in patients treated with csDMARDs is a retrospective, longitudinal study of a population-based RA cohort using an administrative database including a total of 27,710 individuals with RA and providing 162,710 person-years of follow-up [51]. Use of csDMARDs without corticosteroids was associated with a small decrease in mild infection risk (adjusted rate ratio [RR] 0.90, 95% confidence interval [95% CI] 0.88–0.93) and was not associated with increased serious infection risk (adjusted RR 0.92, 95% CI 0.85–1.0). Similarly, another retrospective analysis conducted on 1993 patients from a claim database demonstrated a slightly reduced risk of hospitalized infection for methotrexate (adjusted RR 0.81, 95% CI 0.70–0.93) and hydroxychloroquine (adjusted RR 0.74, 95% CI 0.62–0.89) [52]. A recent systematic review and meta-analysis of the literature confirmed the lack of an increased risk of infection in patients receiving MTX (RR: 1.14; 95% CI, 0.98–1.34) [53]. However, all these reports provided no data on the risk of stratified infection by pathogen."}

{"project":"LitCovid-sentences","denotations":[{"id":"T71","span":{"begin":0,"end":13},"obj":"Sentence"},{"id":"T72","span":{"begin":14,"end":304},"obj":"Sentence"},{"id":"T73","span":{"begin":305,"end":578},"obj":"Sentence"},{"id":"T74","span":{"begin":579,"end":852},"obj":"Sentence"},{"id":"T75","span":{"begin":853,"end":999},"obj":"Sentence"},{"id":"T76","span":{"begin":1000,"end":1030},"obj":"Sentence"},{"id":"T77","span":{"begin":1031,"end":1123},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"4.2 csDMARDs\nThe most comprehensive analysis of infectious risk in patients treated with csDMARDs is a retrospective, longitudinal study of a population-based RA cohort using an administrative database including a total of 27,710 individuals with RA and providing 162,710 person-years of follow-up [51]. Use of csDMARDs without corticosteroids was associated with a small decrease in mild infection risk (adjusted rate ratio [RR] 0.90, 95% confidence interval [95% CI] 0.88–0.93) and was not associated with increased serious infection risk (adjusted RR 0.92, 95% CI 0.85–1.0). Similarly, another retrospective analysis conducted on 1993 patients from a claim database demonstrated a slightly reduced risk of hospitalized infection for methotrexate (adjusted RR 0.81, 95% CI 0.70–0.93) and hydroxychloroquine (adjusted RR 0.74, 95% CI 0.62–0.89) [52]. A recent systematic review and meta-analysis of the literature confirmed the lack of an increased risk of infection in patients receiving MTX (RR: 1.14; 95% CI, 0.98–1.34) [53]. However, all these reports provided no data on the risk of stratified infection by pathogen."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T59","span":{"begin":160,"end":162},"obj":"Phenotype"},{"id":"T60","span":{"begin":248,"end":250},"obj":"Phenotype"}],"attributes":[{"id":"A59","pred":"hp_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/HP_0001370"},{"id":"A60","pred":"hp_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/HP_0001370"}],"text":"4.2 csDMARDs\nThe most comprehensive analysis of infectious risk in patients treated with csDMARDs is a retrospective, longitudinal study of a population-based RA cohort using an administrative database including a total of 27,710 individuals with RA and providing 162,710 person-years of follow-up [51]. Use of csDMARDs without corticosteroids was associated with a small decrease in mild infection risk (adjusted rate ratio [RR] 0.90, 95% confidence interval [95% CI] 0.88–0.93) and was not associated with increased serious infection risk (adjusted RR 0.92, 95% CI 0.85–1.0). Similarly, another retrospective analysis conducted on 1993 patients from a claim database demonstrated a slightly reduced risk of hospitalized infection for methotrexate (adjusted RR 0.81, 95% CI 0.70–0.93) and hydroxychloroquine (adjusted RR 0.74, 95% CI 0.62–0.89) [52]. A recent systematic review and meta-analysis of the literature confirmed the lack of an increased risk of infection in patients receiving MTX (RR: 1.14; 95% CI, 0.98–1.34) [53]. However, all these reports provided no data on the risk of stratified infection by pathogen."}

{"project":"2_test","denotations":[{"id":"32205186-18668604-4826892","span":{"begin":300,"end":302},"obj":"18668604"},{"id":"32205186-18260176-4826893","span":{"begin":848,"end":850},"obj":"18260176"}],"text":"4.2 csDMARDs\nThe most comprehensive analysis of infectious risk in patients treated with csDMARDs is a retrospective, longitudinal study of a population-based RA cohort using an administrative database including a total of 27,710 individuals with RA and providing 162,710 person-years of follow-up [51]. Use of csDMARDs without corticosteroids was associated with a small decrease in mild infection risk (adjusted rate ratio [RR] 0.90, 95% confidence interval [95% CI] 0.88–0.93) and was not associated with increased serious infection risk (adjusted RR 0.92, 95% CI 0.85–1.0). Similarly, another retrospective analysis conducted on 1993 patients from a claim database demonstrated a slightly reduced risk of hospitalized infection for methotrexate (adjusted RR 0.81, 95% CI 0.70–0.93) and hydroxychloroquine (adjusted RR 0.74, 95% CI 0.62–0.89) [52]. A recent systematic review and meta-analysis of the literature confirmed the lack of an increased risk of infection in patients receiving MTX (RR: 1.14; 95% CI, 0.98–1.34) [53]. However, all these reports provided no data on the risk of stratified infection by pathogen."}